Abstract: This method for imaging in real time the propagation of a mechanical wave in an acoustically propagative medium comprises steps of: a) emitting (1000) a mechanical wave in an acoustically propagative medium, using an acoustic source being placed in an emission region of the acoustically propagative medium, b) measuring (1002) voltage signal waveform values at a reception region, using an acoustic measurement unit; c) calculating (1004) acoustic field values in the acoustically propagative medium, between the emission region and the reception region, using a reconstruction algorithm implemented in a signal processing unit, and the signal waveform values measured during step b) d) generating an image, using an image generation device and using the calculated acoustic field values.

Abstract: A method and apparatus of a device that classifies a mesothelioma image is described. In an exemplary embodiment, the device segments the mesothelioma image into a region of interest that includes information useful for classification, and a background region, by applying a first convolutional neural network. In addition, the device tiles the region of interest into a set of tiles. For each tile, the device extracts a feature vector of that tile by applying a second convolutional neural network, where the features of the feature vectors represent local descriptors of the tile. Furthermore, the device processes the extracted feature vectors of the set of tiles to classify the image.

Abstract: A transcriptomic signature based on Human endogenous retroviruses (HERVs) expression to characterize leukemic stem cells. In particular, determining the presence of Leukemic Stem Cells (LSCs) in a patient. In an aspect, determining the presence of, or quantifying, LSCs in a patient. Also, gene-related methods for the identification of high-risk acute myeloid leukemia (AML) patients, methods of predicting response to treatment, methods to evaluate (minimal) residual disease during follow-up, methods to determine relapse risk, and methods of treatment of patients following implementation of the former methods.

Abstract: The use of a transcriptomic signature based on HERVs expression to characterize new AML subtypes, and a method to determine to which AML subtype a patient pertains. The method includes providing relationship between the 9 AML sub-types and HERVs characterized by their specific herv_id and their relationship with one of these AML subtypes, determining from a patient cell sample HERVs expression profile, determining which of the 9 AML subtypes is the most represented based on HERV expression in the cell sample, and attributing to the patient the most represented AML subtype among the 9 AML subtypes. The method allows identifying patients with medium good or bad prognosis and treating the same with a cancer therapy against AML.

Abstract: The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.

Abstract: The present invention relates to a non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject said method comprising the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. The present invention also relates to antagonist of ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model, reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.

Abstract: A computer-implemented method for generating a registered image (Breg) based on at least one first image of an object compliant with a source imaging modality and on at least one second image of the object compliant with a target imaging modality. The object may include a human body part, and the structures of interest may include stiff regions such as bones, cartilage, or tendons.

Abstract: A computer-implemented method for reconstructing a 3D image of a human body part studied of a subject from at least one 2D projection of the human body part studied of the subject and a generative network trained for reconstructing 3D images. The human body part may be the head and/or the neck.

Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.

Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.

Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.

Abstract: A non invasive diagnostic method of pancreatic ductal adenocarcinoma (PDAC) in a subject is provided. The method comprises the step of measuring the level of ?ig-h3 protein in a blood sample wherein the serum level of ?ig-h3 is positively correlated with the risk of having a PDAC. By following studies on 2 distinct cohorts of 20 and 104 of PDAC patients, and on PDAC mouse model, the inventors show that ?ig-h3 can be directly detected in the blood sample and ?ig-h3 is expressed very early in tumorigenesis in pancreatic neoplastic lesions. Also provided is a ?ig-h3 protein, for use in the treatment of PDAC. The inventors found that ?ig-h3 bind directly on CD8+ T cells by reducing their activation and cytotoxic properties. Furthermore, the use of neutralizing ?ig-h3 antibodies in PDAC mouse model reduced tumor growth by enhancing CD8+ T cell anti-tumoral response.

Abstract: Method and system for localizing a region of interest in a medium in which cavitation occurs. Method for localizing a region of interest (R) in a medium (M) in which cavitation occurs, the method comprising the steps consisting in: producing cavitation in the region of interest (R), the cavitation generating an acoustic signal, at each of at least three separate positions, detecting a cavitation signal representative of the acoustic signal of the cavitation, for at least two pairs of cavitation signals, determining a delay between the cavitation signals of each pair of cavitation signals, calculating a localization of the region of interest (R) based on the delays and the positions.

Abstract: This method, for determining the local intensity (I0) of an acoustic field propagating in a target region of a soft solid, at a position located within said target region, includes at least the following steps: determining (102) a value of an ultrasound attenuation coefficient (?) of the soft body in the target region; determining (104) a value of the shear modulus (?) of the soft body in the target region; determining (106) a value of the speed of sound (c) in the target region of the soft body; and building (110), with the values determined in steps a), b) and c), a viscoelastic model (M) of a steady-state displacement induced by an acoustic field having a time invariant shape or a viscoelastic model of a difference between two steady-state displacements induced by an acoustic field having a time invariant shape.

Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.

Abstract: This device (2) for generating ultrasonic waves in a target region of a soft solid, includes at least two ultrasound sources (32), light sources (40) distributed around a central axis (X2) of the device (2), for enlightening a zone of the soft solid via subsurface scattering, and a video camera (50), for capturing images of the zone enlightened by the lighting means. The ultrasound source (32), the light sources (40) and the video camera (50) are mounted on a body of the device (20) and oriented toward a common target zone which includes a focal point of the ultrasound sources (32). A boresight of the video camera is aligned on the central axis (X2).

Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Abstract: A method of prognosis of patient outcome and of the resistance to a chemotherapy treatment of an individual afflicted by a tumor. The method involves determining the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO: 1 to SEQ ID NO: 160.